{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T19:54:38Z","timestamp":1789502078920,"version":"build-2803163510"},"reference-count":124,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[1993,7,1]],"date-time":"1993-07-01T00:00:00Z","timestamp":741484800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Pediatr"],"published-print":{"date-parts":[[1993,7]]},"DOI":"10.1007\/bf02751425","type":"journal-article","created":{"date-parts":[[2007,11,19]],"date-time":"2007-11-19T20:43:50Z","timestamp":1195505030000},"page":"485-507","source":"Crossref","is-referenced-by-count":16,"title":["Present status and future prospects of oral iron chelation therapy in thalassaemia and other diseases"],"prefix":"10.1007","volume":"60","author":[{"given":"George J.","family":"Kontoghiorghes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"BF02751425_CR1","first-page":"63","volume":"61","author":"World Health Organisation","year":"1983","unstructured":"World Health Organisation. Community control of hereditary anaemias.WHO Bull 1983; 61: 63\u201380.","journal-title":"WHO Bull"},{"key":"BF02751425_CR2","volume-title":"The Clinical Approach to Thalassaemia","author":"B Modell","year":"1984","unstructured":"Modell B, Berdoukas V.The Clinical Approach to Thalassaemia. London: Grune and Stratton, 1984."},{"key":"BF02751425_CR3","volume-title":"Advances and Controversies in Thalassaemia Therapy, Bone Marrow Transplantation and Other Approaches","year":"1989","unstructured":"Buckner CD, Gale RP, Lucarelli G, eds.Advances and Controversies in Thalassaemia Therapy, Bone Marrow Transplantation and Other Approaches. New York: Alan R. Liss Pub. 1989."},{"key":"BF02751425_CR4","volume-title":"The Thalassaemia Syndromes","author":"DJ Weatherall","year":"1981","unstructured":"Weatherall DJ, Glegg JB.The Thalassaemia Syndromes. 3rd edn. oxford: Blackwell Scientific Publications, 1981.","edition":"3rd edn."},{"key":"BF02751425_CR5","first-page":"27","volume":"55","author":"GJ Kontoghiorghes","year":"1992","unstructured":"Kontoghiorghes GJ. Advances in oral iron chelation in man.Intern J Haematol 1992; 55: 27\u201338.","journal-title":"Intern J Haematol"},{"key":"BF02751425_CR6","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/0003-9861(86)90305-X","volume":"246","author":"B Halliwell","year":"1986","unstructured":"Halliwell B, Gutteridge JMC. Oxygen, free radicals and iron in relation to biology and medicine: Some problems and concepts.Arch Bioch Biophys 1986; 246: 501\u2013514.","journal-title":"Arch Bioch Biophys"},{"key":"BF02751425_CR7","volume-title":"Living with Thalassaemia","author":"MB Agarwal","year":"1986","unstructured":"Agarwal MB.Living with Thalassaemia. Bombay: Bhalani Book Depot 1986."},{"key":"BF02751425_CR8","unstructured":"Angastiniotis M. Cost of desferrioxamine treatment. In: Abstracts,1st International Conference on Oral Chelators (ICOC). London, UK: 1989: 34."},{"key":"BF02751425_CR9","first-page":"33","volume":"121","author":"EB Brown","year":"1983","unstructured":"Brown EB. Thalassaemia.Prog Clin Biol Res 1983; 121: 33\u201342.","journal-title":"Prog Clin Biol Res"},{"key":"BF02751425_CR10","first-page":"1","volume-title":"Development of iron chelators for clinical use","year":"1975","unstructured":"Anderson WF, Hiller MC, eds. Development of iron chelators for clinical use. National Institute of Health. Bethesda, U.S.A. 1975: 1\u2013277."},{"key":"BF02751425_CR11","first-page":"1","volume-title":"Development of Iron Chelators for Clinical Use","year":"1980","unstructured":"Martell A.E., Anderson WF, Badman DG, eds.Development of Iron Chelators for Clinical Use. Amsterdam: Elsevier Scientific Publishers, 1980; 1\u2013311."},{"key":"BF02751425_CR12","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1021\/jm00356a037","volume":"26","author":"S Avramovici-Grisaru","year":"1983","unstructured":"Avramovici-Grisaru S, Sarel S, Link G, Hershko C. Synthesis of iron Bis (pyridoxal isonicotinoyl hydrazones) and thein vivo iron removal properties of some pyridoxal derivatives.J Med Chem 1983; 26: 298\u2013302.","journal-title":"J Med Chem"},{"key":"BF02751425_CR13","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1146\/annurev.nu.01.070181.000331","volume":"1","author":"JB Neilands","year":"1981","unstructured":"Neilands JB. Iron absorption and transport in micro-organisms.Ann Rev Nutr 1981; 1: 27\u201346.","journal-title":"Ann Rev Nutr"},{"key":"BF02751425_CR14","series-title":"British Library Microfilm No. D66194\/86","volume-title":"The Design of Orally Active Iron Chelators for the Treatment of Thalassaemia","author":"GJ Kontoghiorghes","year":"1982","unstructured":"Kontoghiorghes GJ:The Design of Orally Active Iron Chelators for the Treatment of Thalassaemia. PhD thesis, University of Essex, Colchester, UK. British Library Microfilm No. D66194\/86, 1982."},{"key":"BF02751425_CR15","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S0140-6736(80)92721-X","volume":"ii","author":"ST Callender","year":"1980","unstructured":"Callender ST, Weatherall DJ. Iron chelation with oral desferrioxamine.Lancet 1980: ii: 689.","journal-title":"Lancet"},{"key":"BF02751425_CR16","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/S0140-6736(83)90413-0","volume":"ii","author":"GJ Kontoghiorghes","year":"1983","unstructured":"Kontoghiorghes GJ, Marcus RE, Huehns ER. Desferrioxamine suppositories.Lancet 1983; ii: 454.","journal-title":"Lancet"},{"key":"BF02751425_CR17","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1200\/JCO.1992.10.1.117","volume":"10","author":"JL Speyer","year":"1992","unstructured":"Speyer JL, Green MD, Zeleniuch-Jaquotte A et al. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer.J Clin Oncol 1992; 10: 117\u2013127.","journal-title":"J Clin Oncol"},{"key":"BF02751425_CR18","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1093\/ajcp\/25.3.266","volume":"25","author":"TJ Greenwalt","year":"1955","unstructured":"Greenwalt TJ, Ayers VI. Calcium disodium EDTA in transfusion haemosiderosis.Am J Clin Pathol 1955: 25: 266\u2013271.","journal-title":"Am J Clin Pathol"},{"key":"BF02751425_CR19","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/j.1600-0609.1986.tb02282.x","volume":"36","author":"MJ Pippard","year":"1986","unstructured":"Pippard MJ, Jackson MJ, Hoffman K et al. Iron chelation using subcutaneous infusion of diethylene triamine penta-acetic acid (DTPA).Scand J Haematol 1986; 36: 466\u2013472.","journal-title":"Scand J Haematol"},{"key":"BF02751425_CR20","first-page":"342","volume":"209","author":"CM Peterson","year":"1976","unstructured":"Peterson CM, Graziano JH, Grady RW et al. Chelation studies with 2, 3-dihydroxybenzoic acid in patients with thalassaemia major.Br J Haematol 1976; 209: 342\u2013348.","journal-title":"Br J Haematol"},{"key":"BF02751425_CR21","first-page":"342","volume":"209","author":"RW Grady","year":"1979","unstructured":"Grady RW, Peterson CM, Jones RL et al. Rhodotorulic acid-investigation of its potenial as an iron chelating drug.J Pharmacol Exp Ther 1979; 209: 342\u2013348.","journal-title":"J Pharmacol Exp Ther"},{"key":"BF02751425_CR22","first-page":"415","volume":"344","author":"A Cerami","year":"1980","unstructured":"Cerami A, Grady RW, Peterson CM et al. The status of new iron chelators.Ann NY Acid Sci 1980; 344: 415\u2013435.","journal-title":"Ann NY Acid Sci"},{"key":"BF02751425_CR23","first-page":"112","volume":"27","author":"GM Brittenham","year":"1990","unstructured":"Brittenham GM. Pyridoxal isonicotinoyl hydrazone, an effective chelator after oral administration.Semi Haematol 1990; 27: 112\u2013116.","journal-title":"Semi Haematol"},{"key":"BF02751425_CR24","first-page":"213","volume-title":"Development of Iron Chelators For Clinical Use","author":"BR Byers","year":"1975","unstructured":"Byers BR, Arceneaux JEL, Gaimes CG et al. Isolation of microbial iron chelators. Some possible effects of their chemotherapeutic use. In: Anderson WF, Hiller MC, eds.Development of Iron Chelators For Clinical Use. National Institute of Health, Bethesda, USA. 1975: 213\u2013228."},{"key":"BF02751425_CR25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0305-7372(91)90002-H","volume":"18","author":"J Koning","year":"1991","unstructured":"Koning J, Palmer P, Franks GR et al. Cardioxane-ICRF 187. Towards anticancer drug specificity through selective toxicity reduction.Cancer Treat Rev 1991: 18: 1\u201319.","journal-title":"Cancer Treat Rev"},{"key":"BF02751425_CR26","first-page":"65a","volume":"76","author":"AS Khalifa","year":"1990","unstructured":"Khalifa AS, Sallam TH, Ghaleb H et al. Salicyl-hydroxamic acid (SHAM); a new oral iron chelator for transfusion induced hemosiderosis in beta thalassaemia major.Blood 1990; 76: 65a.","journal-title":"Blood"},{"key":"BF02751425_CR27","first-page":"95","volume":"27","author":"WR Grady","year":"1990","unstructured":"Grady WR, Hershko C. An evaluation of the potential of HBED as an orally effective iron chelating drug.Semin Haematol 1990; 27 95\u2013100.","journal-title":"Semin Haematol"},{"key":"BF02751425_CR28","unstructured":"Grady RW, Giardina PJ, Salbe AD et al. HBED: Evaluation as an orally effective iron chelator. Abstracts,4th International Conference on Oral Chelators, ICOC, Limassol, Cyprus. 1993: 22."},{"key":"BF02751425_CR29","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/j.1749-6632.1990.tb24321.x","volume":"612","author":"GJ Kontoghiorghes","year":"1990","unstructured":"Kontoghiorghes GJ. Design, properties and effective use of the oral chelator L1 and other \u03b1-ketohydroxypyridines in the treatment of transfusional iron overload in thalassaemia.Ann NY Acad Sci 1990; 612: 339\u2013350.","journal-title":"Ann NY Acad Sci"},{"key":"BF02751425_CR30","first-page":"670","volume":"30","author":"GJ Kontoghiorghes","year":"1986","unstructured":"Kontoghiorghes GJ. Orally active \u03b1-ketohydroxypyridine iron chelators: studies in mice.Mol Pharmacol 1986; 30: 670\u2013673.","journal-title":"Mol Pharmacol"},{"key":"BF02751425_CR31","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S0020-1693(00)84951-8","volume":"152","author":"GJ Kontoghiorghes","year":"1988","unstructured":"Kontoghiorghes GJ, Sheppard L, Barr J. Synthetic methods andin vitro iron binding studies of the novel 1-alkyl-2-ethyl-3-hydroxypyrid-4-ones.Inorg Chim Acta; 1988; 152:192\u2013199.","journal-title":"Inorg Chim Acta"},{"key":"BF02751425_CR32","unstructured":"Kontoghiorghes GJ, Sheppard LN. Process for producing pyrid-4-ones.European Patent Application 1989; No. 0335745."},{"key":"BF02751425_CR33","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/ajh.2830420403","volume":"42","author":"GJ Kontoghiorghes","year":"1993","unstructured":"Kontoghiorghes GJ, Barr J, Nortey P et al. Selection of a new generation of orally active \u03b1-ketohydroxypyridine iron chelators intended for use in the treatment of iron overload.Am J Haematol 1993; 42: 440\u2013444.","journal-title":"Am J Haematol"},{"key":"BF02751425_CR34","first-page":"66a","volume":"76","author":"GJ Kontoghiorghes","year":"1990","unstructured":"Kontoghiorghes GJ, Sheppard LN, Hoffbrand AV et al. 1-Ethyl-2-methyl-3-hydroxypyrid-4-one(L1NEt). A new orally effective iron chelator for the treatment of transfusional iron overload.Blood 1990; 76: 66a.","journal-title":"Blood"},{"key":"BF02751425_CR35","unstructured":"Porter JB, Weir TB, Marshall L et al. Clinical trials with the orally active hydroxypyridone CP94: Implications for future strategies in iron chelation therapy. Abstracts, 4thInternational Conference on Oral Chelators, ICOC. Limassol, Cyprus 1993: 18."},{"key":"BF02751425_CR36","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1182\/blood.V72.5.1497.1497","volume":"72","author":"JB Porter","year":"1988","unstructured":"Porter JB, Gyparaki M, Burker LC et al. Iron mobilisation from hepatocyte monolayer cultures by chelators: The importance of membrane permeability and iron-binding constants.Blood 1988; 72: 1497\u20131503.","journal-title":"Blood"},{"key":"BF02751425_CR37","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1182\/blood.V76.11.2389.2389","volume":"76","author":"JB Porter","year":"1990","unstructured":"Porter JB, Morgan JM, Hoyes KP et al. Relative efficacy and toxicity of hydroxypyridin-4-one iron chelators.Blood 1990; 76: 2389\u20132396.","journal-title":"Blood"},{"key":"BF02751425_CR38","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1182\/blood.V79.7.1882.1882","volume":"79","author":"RJ Bergeron","year":"1992","unstructured":"Bergeron RJ, Streiff RR, Wiegand J et al. A comparison of the iron-clearing properties of 1, 2-dimethyl-3-hydroxy-pyrid-4-one, 1, 2-diethyl-3-hydroxy-pyrid-4-one and deferioxamine.Blood 1992; 79: 1882\u20131890.","journal-title":"Blood"},{"key":"BF02751425_CR39","unstructured":"Grady R, Srinivasan R, Lemeft R et al. DMHP (L1) and DEHP (CP94): Evidence of toxicity in rats. Abstracts, 3rdInternational Conference on Oral Chelators, ICOC. Nice, France 1991: 11."},{"key":"BF02751425_CR40","first-page":"659","volume":"43","author":"LN Sheppard","year":"1993","unstructured":"Sheppard LN, Kontoghiorghes GJ, Competition between deferiprone, desferrioxamine and other chelators for iron and the effect of other metals.Drug Res 1993; 43: 659\u2013663.","journal-title":"Drug Res"},{"key":"BF02751425_CR41","first-page":"1099","volume":"37","author":"GJ Kontoghiorghes","year":"1987","unstructured":"Kontoghiorghes GJ, Sheppard LN, Chambers S. New synthetic approach and iron chelating studies of 1-alkyl-2-methyl-3-hydroxypyrid-4-ones.Drug Res 1987; 37: 1099\u20131102.","journal-title":"Drug Res"},{"key":"BF02751425_CR42","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0020-1693(00)82997-7","volume":"183","author":"RJ Motekaitis","year":"1991","unstructured":"Motekaitis RJ, Martell AE. Stabilities of the iron (III) chelates of 1, 2-dimethyl-3-hydroxy-4-pyridinone and related ligands.Inorg Chim Acta 1991; 183: 71\u201380.","journal-title":"Inorg Chim Acta"},{"key":"BF02751425_CR43","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1042\/bj2410087","volume":"241","author":"GJ Kontoghiorghes","year":"1987","unstructured":"Kontoghiorghes GJ, Chambers S, Hoffbrand AV. Comparative study of iron mobilisation from haemosiderin, ferritin and iron (III) precipitates by chelators.Biochem J 1987; 241: 87\u201392.","journal-title":"Biochem J"},{"key":"BF02751425_CR44","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/0167-4838(86)90288-8","volume":"869","author":"GJ Kontoghiorghes","year":"1986","unstructured":"Kontoghiorghes GJ. The study of iron mobilisation from transferrin using \u03b1-ketohydroxy heteroaromatic chelators.Biochim Biophys Acta 1986; 869: 141\u2013146.","journal-title":"Biochim Biophys Acta"},{"key":"BF02751425_CR45","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0304-4165(86)90164-9","volume":"882","author":"GJ Kontoghiorghes","year":"1986","unstructured":"Kontoghiorghes GJ. Iron mobilisation from lactoferrin by chelators at physiological pH.Biochem Biophys Acta 1986; 882: 267\u2013270.","journal-title":"Biochem Biophys Acta"},{"key":"BF02751425_CR46","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0020-1693(00)81178-0","volume":"138","author":"GJ Kontoghiorghes","year":"1987","unstructured":"Kontoghiorghes GJ. Decreased solubilisation of ferritin iron and fresh iron (III) precipitate following repeated chelator treatments.Inorg Chim Acta 1987; 138: 36\u201340.","journal-title":"Inorg Chim Acta"},{"key":"BF02751425_CR47","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1159\/000205877","volume":"78","author":"GJ Kontoghiorghes","year":"1987","unstructured":"Kontoghiorghes GJ. Orally active \u03b1-ketohydroxypyridine iron chelators. Effects on iron and other metal mobilisations.Acta Haematol 1987; 78: 212\u2013216.","journal-title":"Acta Haematol"},{"issue":"suppl. A","key":"BF02751425_CR48","first-page":"29","volume":"28","author":"K Ganeshaguru","year":"1992","unstructured":"Ganeshaguru K, Lally KM, Piga A et al. Cytotoxic mechanisms of iron chelators.Drugs Today 1992; 28 (suppl. A): 29\u201334.","journal-title":"Drugs Today"},{"key":"BF02751425_CR49","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3109\/10715768609088062","volume":"2","author":"GJ Kontoghiorghes","year":"1986","unstructured":"Kontoghiorghes GJ, Jackson MI, Lunec J.In vitro screening of iron chelators using models of free radical damage.Free Radic Res Commun 1986; 2: 115\u2013124.","journal-title":"Free Radic Res Commun"},{"key":"BF02751425_CR50","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/0014-5793(86)80813-4","volume":"204","author":"GJ Kontoghiorghes","year":"1986","unstructured":"Kontoghiorghes GJ, Piga A, Hoffbrand AV. Cytotoxic effects of the lipophilic iron chelator omadine.FEBS LETT 1986; 204: 208\u2013212.","journal-title":"FEBS LETT"},{"issue":"suppl. 1","key":"BF02751425_CR51","first-page":"381","volume":"77","author":"JM Cunningham","year":"1991","unstructured":"Cunningham JM, Hunter A, Francis GE et al. Differrential cytotoxicity of oral iron chelators and desferrioxamine to human bone marrow haemopoietic progenitor cellsin vitro.Br J Haematol 1991; 77 (suppl. 1): 381.","journal-title":"Br J Haematol"},{"key":"BF02751425_CR52","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0140-6736(84)91298-4","volume":"ii","author":"M Sharnetzky","year":"1984","unstructured":"Sharnetzky M, Konig R Lamomek M et al. Prophylaxis of systemic yersiniasis in Thalassaemia major.Lancet 1984: ii: 791.","journal-title":"Lancet"},{"key":"BF02751425_CR53","unstructured":"Boelaert JR, de Locht M, Schneider YJ. Mucormycosis and desferrioxamine (DFO), Susceptibility of different zygomycetes to DFO. Abstracts, 4thInternational Conference on Iron Chelators, ICOC. Limassol, Cyprus 1993: 13."},{"key":"BF02751425_CR54","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/ki.1989.301","volume":"36","author":"J Cutsem Van","year":"1989","unstructured":"Van Cutsem J, Boelaert JR. Effects of deferoxamine, feroxamine and iron on experimental mucormycosis (zygomycosis).Kidney Inter 1989; 36: 1061\u20131068.","journal-title":"Kidney Inter"},{"key":"BF02751425_CR55","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1574-6968.1988.tb02490.x","volume":"47","author":"JH Brock","year":"1988","unstructured":"Brock JH, Liceaga J, Kontoghiotghes GJ. The effect of synthetic iron chelators on bacterial growth in human serum.FEMS Microbiol Immunol 1988; 47: 55\u201360.","journal-title":"FEMS Microbiol Immunol"},{"key":"BF02751425_CR56","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1128\/MMBR.42.1.45-66.1978","volume":"42","author":"ED Weinberg","year":"1978","unstructured":"Weinberg ED. Iron and infection.Microbiol Rev 1978; 42: 45\u201366.","journal-title":"Microbiol Rev"},{"key":"BF02751425_CR57","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1136\/bmj.295.6612.1509","volume":"2295","author":"GJ Kontoghiorghes","year":"1987","unstructured":"Kontoghiorghes GJ, Aldouri MA, Hoffbrand AV et al. Effective chelation of iron in \u03b2-thalassaemia with the oral chelator 1, 2-dimethyl-3-hydroxypyrid-4-one.Br Med J 1987; 2295: 1509\u20131512.","journal-title":"Br Med J"},{"key":"BF02751425_CR58","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/S0140-6736(87)90545-9","volume":"i","author":"GJ Kontoghiorghes","year":"1987","unstructured":"Kontoghiorghes GJ, Aldouri MA, Sheppard LN et al. 1, 2-Dimethyl-3-hydroxypyrid-4-one, on orally active chelator for the treatment of transfusional iron overload.Lancet 1987; i: 1294\u20131295.","journal-title":"Lancet"},{"key":"BF02751425_CR59","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/j.1365-2141.1990.tb07915.x","volume":"76","author":"P Tondury","year":"1990","unstructured":"Tondury P, Kontoghiorghes GJ, Ridolfi-Luthy R et al. L1 (1, 2-dimethyl-3-hydroxypyrid-4-one) for oral iron chelation in patients with \u03b2-thalassaemia major.Br J Haematol 1990; 76: 550\u2013553.","journal-title":"Br J Haematol"},{"key":"BF02751425_CR60","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/0140-6736(90)92962-H","volume":"ii","author":"NF Olivieri","year":"1990","unstructured":"Olivieri NF, Koren G, Hermann C et al. Comparison of oral iron chelator L1 and desferrioxamine in iron loaded patients.Lancet 1990; ii: 1275\u20131279.","journal-title":"Lancet"},{"key":"BF02751425_CR61","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/0140-6736(90)90380-N","volume":"i","author":"MB Agarwal","year":"1990","unstructured":"Agarwal MB, Viswanathan C, Ramanathan J et al. Oral iron chelation with L1.Lancet 1990; i: 601.","journal-title":"Lancet"},{"key":"BF02751425_CR62","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1365-2141.1990.tb07887.x","volume":"76","author":"GJ Kontoghiorghes","year":"1990","unstructured":"Kontoghiorghes GJ, Bartlett AN, Hoffbrand AV et al. Long term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). (1) Iron chelation and metabolic studies.Br J Haematol 1990; 76: 295\u2013300.","journal-title":"Br J Haematol"},{"issue":"suppl. A","key":"BF02751425_CR63","first-page":"133","volume":"28","author":"R Goudsmit","year":"1992","unstructured":"Goudsmit R, Kersten MJ. Long term treatment of transfusion hemosiderosis with the oral iron chelator L1.Drugs Today 1992; 28 (suppl. A): 133\u2013135.","journal-title":"Drugs Today"},{"issue":"suppl A","key":"BF02751425_CR64","first-page":"137","volume":"28","author":"LG Korkina","year":"1992","unstructured":"Korkina LG, Afanas'ev IB, Deeva IB et al. Free radical status of blood of patients with iron overload: the effect of chelating treatment.Drugs Today 1992; 28 (suppl A): 137\u2013141.","journal-title":"Drugs Today"},{"issue":"suppl A","key":"BF02751425_CR65","first-page":"143","volume":"28","author":"M Jaeger","year":"1992","unstructured":"Jaeger M, Aul C, Sohngen D et al. Iron overload in polytransfused patients with MDS; Use of L1 for oral iron chelation.Drugs Today 1992; 28 (suppl A): 143\u2013147.","journal-title":"Drugs Today"},{"issue":"suppl. A","key":"BF02751425_CR66","first-page":"119","volume":"28","author":"V Carnelli","year":"1992","unstructured":"Carnelli V, Spadaro C, Stefano V et al. L1 efficacy and toxicity in poorly compliant and for refractory to desferrioxamine thalassaemia patients: Interim report.Drugs Today 1992; 28 (suppl. A): 119\u2013121.","journal-title":"Drugs Today"},{"key":"BF02751425_CR67","unstructured":"Kontoghiorghes GJ, Barr J, Baillot R. Studies of aluminium mobilisation in renal dialysis patients using the oral chelator 1, 2-dimethyl-3-hydroxypyrid-4-one.Drug Res (In Press)."},{"key":"BF02751425_CR68","first-page":"35","volume":"9","author":"G Vreugdenhil","year":"1991","unstructured":"Vreugdenhil G, Kontoghiorghes GJ, Van Eijk HG et al. Impaired erythropoietin responsiveness to the anemia in rheumatoid arthritis. A possible inverse relationship with iron stores and effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one.Clin Exp Rheumatol 1991; 9: 35\u201340.","journal-title":"Clin Exp Rheumatol"},{"issue":"suppl A","key":"BF02751425_CR69","first-page":"1","volume":"28","author":"Oral chelation in the treatment of thalassaemia and other diseases","year":"1992","unstructured":"Oral chelation in the treatment of thalassaemia and other diseases.Drugs Today 1992; 28 (suppl A): 1\u2013187.","journal-title":"Drugs Today"},{"issue":"Suppl. A","key":"BF02751425_CR70","first-page":"123","volume":"28","author":"NF Olivieri","year":"1992","unstructured":"Olivieri NF, Koren G, Matsuii D et al. Reduction of tissue iron stores and normalisation of serum ferritin during treatment with the oral iron chelator L1 in thalassaemia intermedia.Drugs Today 1992; 28 (Suppl. A): 123\u2013132.","journal-title":"Drugs Today"},{"key":"BF02751425_CR71","unstructured":"Tondury P. L1 for oral chelation in patients with thalassaemia: results of clinical trials in Switzerland. Abstracts, 4thInternational Conference on Iron Chelators, ICOC. Limassol, Cyprus 1993: 24."},{"key":"BF02751425_CR72","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/clpt.1990.147","volume":"48","author":"GJ Kontoghiorghes","year":"1990","unstructured":"Kontoghiorghes GJ, Goddard JG, Bartlett AN et al. Pharmacokinetic studies in humans with the oral iron chelator 1, 2-dimethyl-3-hydroxypyrid-4-one.Clin Pharm Ther 1990; 48: 255\u2013261.","journal-title":"Clin Pharm Ther"},{"issue":"suppl. A","key":"BF02751425_CR73","first-page":"55","volume":"28","author":"YE Rahman","year":"1992","unstructured":"Rahman YE, Railkar AM, Venkataram S. Pharmacodynamics and pharmacokinetics of 1, 2-dimethyl-3-hydroxypyrid-4-one (DMHP) or L1 in rat, rabbit and dog models.Drugs Today 1992; 28 (suppl. A): 55\u201363.","journal-title":"Drugs Today"},{"key":"BF02751425_CR74","unstructured":"Kontoghiorghes GJ. Metabolism and site of action of L1 (deferiprone). No evidence that L1 biotransformation effects iron excretion. Abstracts, 4thInternational Conference on Iron Chelators, ICOC. Limassol Cyprus 1993: 20."},{"issue":"Suppl A","key":"BF02751425_CR75","first-page":"3","volume":"28","author":"L Sheppard","year":"1992","unstructured":"Sheppard L, Kontoghiorghes GJ. Synthesis and metabolism of L1 and other novel alpha-ketohydroxypyridine iron chelators and their metal complexes.Drugs Today 1992; 28 (Suppl A): 3\u201310.","journal-title":"Drugs Today"},{"key":"BF02751425_CR76","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1749-6632.1990.tb24324.x","volume":"612","author":"NF Olivieri","year":"1990","unstructured":"Olivieri NF, Templeton DM, Koren G et al. Evaluation of the oral iron chelator 1, 2-3-dimethyl-3-hydroxypyrid-4-one (L1) in iron loaded patients.Ann NY Acad Sci 1990; 612: 369\u2013377.","journal-title":"Ann NY Acad Sci"},{"issue":"suppl. A","key":"BF02751425_CR77","first-page":"45","volume":"28","author":"P Nielsen","year":"1992","unstructured":"Nielsen P, Frtjes M, Drescow B et al. The iron-decorporating effect of L1 in normal and TMH-ferrocene iron loaded rats and in one patient with post-transfusional siderosis as judged by59Fe-labelling technique.Drugs Today 1992; 28 (suppl. A): 45\u201353.","journal-title":"Drugs Today"},{"key":"BF02751425_CR78","first-page":"1332","volume":"40","author":"GJ Kontoghiorghes","year":"1990","unstructured":"Kontoghiorghes GJ. Chelators affecting iron absorption in mice.Drug Res 1990; 40: 1332\u20131335.","journal-title":"Drug Res"},{"issue":"Suppl. 1","key":"BF02751425_CR79","first-page":"10","volume":"74","author":"GJ Kontoghiorghes","year":"1990","unstructured":"Kontoghiorghes GJ, Bartlett AN, Hoffbrand AV et al. Intensive chelation and metabolic studies using oral 1, 2-dimethyl-3-hydroxypryrid-4-one (L1).Br J Haematol 1990; 74 Suppl. 1: 10.","journal-title":"Br J Haematol"},{"issue":"Suppl A","key":"BF02751425_CR80","first-page":"19","volume":"28","author":"RW Evans","year":"1992","unstructured":"Evans RW, Sharma M, Ogwang W et al. The effect of alpha-ketohydroxypyridine chelators on transferrin saturationin vitro andin vivo.Drugs Today 1992; 28 (Suppl A): 19\u201323.","journal-title":"Drugs Today"},{"key":"BF02751425_CR81","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/j.1365-2141.1992.tb06445.x","volume":"82","author":"MB Agarwal","year":"1992","unstructured":"Agarwal MB, Gupta SS, Viswanathan C et al. Long term assessment of efficacy and safety of L1, an oral iron chelator in transfusion dependent thalassaemia: Indian trial.Br J Haematol 1992;82:460\u2013466.","journal-title":"Br J Haematol"},{"issue":"Suppl A","key":"BF02751425_CR82","first-page":"107","volume":"28","author":"MB Agarwal","year":"1992","unstructured":"Agarwal MB, Gupta SS, Viswanathan C et al. Long term assessment of efficacy and toxicity of L1 (1, 2-dimethyl-3-hydroxypyrid-4-one) in transfusion dependent thalassaemia. Indian trial.Drugs Today 1992;28(Suppl A):107\u2013114.","journal-title":"Drugs Today"},{"issue":"Suppl A","key":"BF02751425_CR83","first-page":"115","volume":"28","author":"P Tondury","year":"1992","unstructured":"Tondury P, Wagner HP, Kontoghiorghes GJ. Update of long-term clinical trials with L1 in beta-thalassaemia patients in Berne, Switzerland.Drugs Today 1992;28 (Suppl A):115\u2013117.","journal-title":"Drugs Today"},{"key":"BF02751425_CR84","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1136\/adc.63.3.250","volume":"63","author":"S Virgilis De","year":"1988","unstructured":"De Virgilis S, Cognia M, Turco MP et al. Depletion of trace elements and acute occular toxicity induced by desferrioxamine in patients with thalassaemia.Arch Dis Child 1988;63:250\u2013255.","journal-title":"Arch Dis Child"},{"key":"BF02751425_CR85","unstructured":"Zaino EC. Deferrioxamine and trance metal excretion In: Zaino EC, and Roberts RH, eds.Chelation Therapy in Chronic Iron Overload. Symposia Specialist Pub. Miami: U.S.A. 1977:95\u2013101."},{"key":"BF02751425_CR86","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1182\/blood.V80.3.593.593","volume":"80","author":"FN Alrefai","year":"1992","unstructured":"Alrefai FN, Wonke B, Hoffbrand AV et al. Efficacy and possible adverse effects of the oral iron chelator 1, 2-dimethyl-3-hydroxypyrid-4-one (L1) in thalassaemia major.Blood 1992;80:593\u2013599.","journal-title":"Blood"},{"key":"BF02751425_CR87","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1136\/bmj.303.6813.1279","volume":"303","author":"GJ Kontoghiorghes","year":"1991","unstructured":"Kontoghiorghes GJ. Oral iron chelation is here.Br Med J 1991;303:1279\u20131280.","journal-title":"Br Med J"},{"key":"BF02751425_CR88","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1600-0609.1986.tb01773.x","volume":"37","author":"GJ Kontoghiorghes","year":"1986","unstructured":"Kontoghiorghes GJ. Dose response studies using desferrioxamine and orally active chelators in a mouse model.Scand J Haematol 1986;37:63\u201370.","journal-title":"Scand J Haematol"},{"key":"BF02751425_CR89","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1136\/jcp.40.4.404","volume":"40","author":"GJ Kontoghiorghes","year":"1987","unstructured":"Kontoghiorghes GJ, Sheppard LN, Hoffbrand AV et al. Iron chelation studies using desferrioxamine and the potential oral chelator 1, 2-dimethyl-3-hydroxypyrid-4-one in normal and iron loaded rats.J Clin Path 1987;40:404\u2013408.","journal-title":"J Clin Path"},{"key":"BF02751425_CR90","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0140-6736(89)90642-9","volume":"ii","author":"GJ Kontoghiorghes","year":"1989","unstructured":"Kontoghiorghes GJ, Nasseri-Sina P, Goddard JG et al. Safety of iron chelator L1.Lancet 1989;ii:457\u2013458.","journal-title":"Lancet"},{"key":"BF02751425_CR91","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0140-6736(89)90206-7","volume":"ii","author":"JB Porter","year":"1989","unstructured":"Porter JB, Hayes KP, Abeysinghe R et al. Animal toxicity of iron chelator L1.Lancet 1989;ii:156.","journal-title":"Lancet"},{"issue":"Suppl A","key":"BF02751425_CR92","first-page":"81","volume":"28","author":"P Nortey","year":"1992","unstructured":"Nortey P, Barr J, Matsakis M et al. Effect on iron excretion and animal toxicology of L1 and other alpha-ketohydroxypyridine chelators.Drugs Today 1992;28 (Suppl A):81\u201388.","journal-title":"Drugs Today"},{"issue":"Suppl A","key":"BF02751425_CR93","first-page":"73","volume":"28","author":"RW Grady","year":"1992","unstructured":"Grady RW, Srinivasan R, Dunn JB et al. Evidence of toxicity due to 1, 2-dimethyl-3-hyydroxypyrid-4-one (L1) in normal rats.Drugs Today 1992;28 (Suppl A):73\u201379.","journal-title":"Drugs Today"},{"key":"BF02751425_CR94","first-page":"1","volume-title":"14-day oral toxicity study in dogs with 1, 2-dimethyl-3-hydroxypyrid-4-one (DMHP L1)","author":"JA Biesemeier","year":"1991","unstructured":"Biesemeier JA, Laveglia J. 14-day oral toxicity study in dogs with 1, 2-dimethyl-3-hydroxypyrid-4-one (DMHP L1).Food and Drug Research Laboratories, Waverley, New York: 1991:1\u2013102 and appendices (I-1)-(V-3)."},{"key":"BF02751425_CR95","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/0140-6736(93)92443-W","volume":"341","author":"V Berdoukas","year":"1993","unstructured":"Berdoukas V, Bentley P, Frost H et al. Toxicity of oral iron chelator L1.Lancet. 1993;341:1088.","journal-title":"Lancet"},{"key":"BF02751425_CR96","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/0140-6736(93)90925-7","volume":"1","author":"GJ Kontoghiorghes","year":"1993","unstructured":"Kontoghiorghes GJ, Agarwal MB, Tondury P et al. Future of oral iron chelator deferriprone (L1).Lancet 1993;1:1479\u20131480.","journal-title":"Lancet"},{"key":"BF02751425_CR97","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/0140-6736(93)92444-X","volume":"343","author":"C Hershko","year":"1993","unstructured":"Hershko C. Development of oral iron chelator L1.Lancet 1993;343:1088\u20131089.","journal-title":"Lancet"},{"key":"BF02751425_CR98","unstructured":"Ciba Report on Desferal. Adverse Drug Reaction Centre. Information No. 2. October 1965. pp 1\u201338."},{"key":"BF02751425_CR99","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/j.1365-2141.1986.tb04082.x","volume":"62","author":"GJ Kontoghiorghes","year":"1986","unstructured":"Kontoghiorghes GJ, Hoffbrand AV. Orally active alpha-ketohydroxypyridine iron chelators intended for clinical use:In vivo studies in rabbits.Br J Haematol 1986;62:607\u2013613.","journal-title":"Br J Haematol"},{"key":"BF02751425_CR100","first-page":"107","volume":"309","author":"GJ Kontoghiorghes","year":"1989","unstructured":"Kontoghiorghes GJ, Bartlett AH, Hoffbrand AV. Prospects for effective oral iron chelation therapy in man with 1,2-dimethyl-3-hydroxypyrid-4-one and other alpha-ketohydroxypyridines.Prog Clin Biol Res 1989;309:107\u2013114.","journal-title":"Prog Clin Biol Res"},{"key":"BF02751425_CR101","unstructured":"Agarwal MB, Gupta SS, Viswanathan G et al. Long term efficacy and toxicity of L1 and iron chelator in transfusion dependent thalassaemics over the last three and a half years. Abstracts,4th International Conference on Oral Chelators, ICOC, Limassol, Cyprus 1993:23."},{"key":"BF02751425_CR102","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0140-6736(89)90641-7","volume":"ii","author":"AV Hoffbrand","year":"1989","unstructured":"Hoffbrand AV, Bartlett AN, Veys P et al. Agranulocytosis and thrombocytopenia in a patient with Blackfan Diamond anaemia during oral chelator trial.Lancet 1989;ii:457.","journal-title":"Lancet"},{"key":"BF02751425_CR103","unstructured":"Kersten MJ, Lange R, Goudsmit R et al. Long term treatment of transfusional iron overload with the oral iron chelator 1, 2-dimethyl-3-hydroxypyrid-4-one. Abstracts,4th International Congress on Oral Chelators, ICOC, Limassol, Cyprus. 1993:27."},{"key":"BF02751425_CR104","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S0308-2261(21)00192-2","volume":"9","author":"GAR Young","year":"1980","unstructured":"Young GAR, Vincent PC. Drug induced agranulocytosis.Clin Haematol 1980;9:483\u2013504.","journal-title":"Clin Haematol"},{"key":"BF02751425_CR105","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1023\/A:1015934104984","volume":"6","author":"JP Uetrecht","year":"1989","unstructured":"Uetrecht JP. Idiosyncratic drug reaction. Possible role of reactive metabolites generated by leukocytes.Pharmacol Res 1989; 6:265\u2013273.","journal-title":"Pharmacol Res"},{"key":"BF02751425_CR106","first-page":"213","volume":"20","author":"JP Uetrecht","year":"1900","unstructured":"Uetrecht JP. Drug metabolism by leukocytes and its role in drug-induced lupus and other idiosyncratic drug reactions.Toxicology 1900;20:213\u2013235.","journal-title":"Toxicology"},{"issue":"Suppl A","key":"BF02751425_CR107","first-page":"149","volume":"28","author":"AV Hoffbrand","year":"1992","unstructured":"Hoffbrand AV, Kontoghiorghes GJ. Protocol for monitoring efficacy and toxicity in clinical trials with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1).Drugs Today 1992;28 (Suppl A):149\u2013155.","journal-title":"Drugs Today"},{"key":"BF02751425_CR108","first-page":"565","volume":"144","author":"MH Freedman","year":"1990","unstructured":"Freedman MH, Grisary D, Olivieri NF et al. Pulmonary syndrome in patients with thalassaemia major receiving intravenous desferioxamine infusions.Am J Dis Child 1990;144:565\u2013569.","journal-title":"Am J Dis Child"},{"key":"BF02751425_CR109","unstructured":"Zervas J, Kyriakou D, Konstantopoulos K et al. Acute myelopathy after high dose desferrioxamine administration intravenously. In: Abstracts3rd International Conference on Thalassaemia and the Haemoglobinopathies. Gagliari. Italy. 1989:162."},{"key":"BF02751425_CR110","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1056\/NEJM198604033141402","volume":"314","author":"NF Olivieri","year":"1986","unstructured":"Olivieri NF, Buncic RJ, Chew E et al. Visual and auditory neurotoxicity in patients receiving subcutaneous desferrioxamine infusions.N Engl J Med 1986; 314:869\u2013873.","journal-title":"N Engl J Med"},{"key":"BF02751425_CR111","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1136\/bmj.291.6493.448","volume":"291","author":"RJ Polson","year":"1985","unstructured":"Polson RJ, Jame A, Bomford A et al. Treatment of rheumatoid arthritis with desferrioxamine: relation between stores of iron before treatment and side effects.Br Med J 1985;291:448.","journal-title":"Br Med J"},{"key":"BF02751425_CR112","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0022-3476(88)80375-5","volume":"113","author":"S Virgillis De","year":"1988","unstructured":"De Virgillis S, Cognia M, Fracia F et al. Desferrioxamine induced growth retardation in patients with thalassaemia major.J Paediatr 1988;113:661\u2013669.","journal-title":"J Paediatr"},{"key":"BF02751425_CR113","unstructured":"Politis C, Vrettou H, Fragatou S et al. Reactions to subcutaneous application of iron chelation therapy with desferri-oxamine. An urgent need for oral chelators. Abstracts,4th International Congress on Oral Chelators, ICOC. Limassol, Cyprus. 1993:4."},{"key":"BF02751425_CR114","first-page":"173","volume":"25","author":"HG Nebeker","year":"1984","unstructured":"Nebeker HG, Milliner DS, Ott SA et al. Aluminium-related osteomalagia. Clinical response to desferrioxamine.Kidney Int 1984;25:173.","journal-title":"Kidney Int"},{"key":"BF02751425_CR115","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S0272-6386(85)80183-9","volume":"6","author":"JA Walker","year":"1985","unstructured":"Walker JA, Sherman RA, Eisenfer RP. Thrombocytopenia associated with intravenous desferrioxamine.Am J Kidney Dis 1985;6:254\u2013256.","journal-title":"Am J Kidney Dis"},{"key":"BF02751425_CR116","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(89)90264-X","volume":"ii","author":"MG Zurlo","year":"1989","unstructured":"Zurlo MG, De Stefano P, Borgna-Pignatti C et al. Survival and causes of death in thalassaemia major.Lancet 1989;ii:27\u201329.","journal-title":"Lancet"},{"key":"BF02751425_CR117","unstructured":"Kurtzman NA, ed. Toxicity from aluminium and iron: Recognition, treatment and prevention.Sem Nephrol 1986; Suppl 1:1\u201341."},{"issue":"Suppl. A","key":"BF02751425_CR118","first-page":"183","volume":"28","author":"GJ Kontoghiorghes","year":"1992","unstructured":"Kontoghiorghes GJ, Barr J, Baillot R. Aluminium mobilisation in renal dialysis patients using the oral chelator 1, 2-dimethyl-3-hydroxypyrid-4-one (L1).Drugs Today 1992;28 (Suppl. A):183\u2013187.","journal-title":"Drugs Today"},{"key":"BF02751425_CR119","first-page":"25","volume":"4","author":"N Giordano","year":"1986","unstructured":"Giordano N, Sancasciani S, Borghi C et al. Antianemic and potential anti-inflammatory activity of desferrioxamine: Possible usefulness in rheumatoid arthritis.Clin Exp Rheumatol 1986;4:25\u201329.","journal-title":"Clin Exp Rheumatol"},{"issue":"Suppl A","key":"BF02751425_CR120","first-page":"157","volume":"28","author":"G Vreugdenhil","year":"1992","unstructured":"Vreugdenhil G, Van Eijk HG, Swaak AJG. Iron and iron chelators in rheumatoid arthritis.Drugs Today 1992;28 (Suppl A):157\u2013163.","journal-title":"Drugs Today"},{"key":"BF02751425_CR121","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1182\/blood.V72.1.358.358","volume":"72","author":"DG Heppner","year":"1988","unstructured":"Heppner DG, Hallaway PE, Kontoghiorghes GJ et al. Antimalaria properties of orally active iron chelators.Blood 1988; 72:358\u2013361.","journal-title":"Blood"},{"key":"BF02751425_CR122","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1182\/blood.V79.2.308.308","volume":"79","author":"VR Gordeuk","year":"1992","unstructured":"Gordeuk VR, Thuma PE, Brittenham GM et al. Iron chelation with desferrioxamine B in adults with asymptomatic P. falciparum parasitemia.Blood 1992;79:308\u2013312.","journal-title":"Blood"},{"key":"BF02751425_CR123","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/0140-6736(91)92978-B","volume":"i","author":"CDR McLachlan","year":"1991","unstructured":"McLachlan CDR, Dalton AJ, Kruck TPA et al. Intramuscular desferrioxamine in patients with Alzheimer's disease.Lancet; 1991;i:1304\u20131308.","journal-title":"Lancet"},{"key":"BF02751425_CR124","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1182\/blood.V69.3.757.757","volume":"69","author":"ZA Estrow","year":"1987","unstructured":"Estrow ZA, Tawa XH, Dube ID et al.In vitro andin vivo effects of desferioxamine in neonatal acute leukaemia.Blood 1987; 69:757\u2013761.","journal-title":"Blood"}],"container-title":["The Indian Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02751425.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF02751425\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02751425","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T10:52:45Z","timestamp":1630147965000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF02751425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1993,7]]},"references-count":124,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1993,7]]}},"alternative-id":["BF02751425"],"URL":"https:\/\/doi.org\/10.1007\/bf02751425","relation":{},"ISSN":["0019-5456","0973-7693"],"issn-type":[{"value":"0019-5456","type":"print"},{"value":"0973-7693","type":"electronic"}],"subject":[],"published":{"date-parts":[[1993,7]]}}}